Genmab A/S (GMAB) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.

Do analysts prefer TAK or GMAB?

Genmab A/S has a consensus target price of $45.20, indicating a potential upside of 92.42%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Genmab A/S	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Which has better earnings & valuation, TAK or GMAB?

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.41T	0.01	$994.06M	$0.55	26.24
Genmab A/S	$19.02B	0.82	$631.91M	$1.20	19.58

Does the media refer more to TAK or GMAB?

In the previous week, Genmab A/S had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 5 mentions for Genmab A/S and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.02 beat Genmab A/S's score of 0.59 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, TAK or GMAB?

Takeda Pharmaceutical has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Does the MarketBeat Community believe in TAK or GMAB?

Genmab A/S received 57 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 62.30% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Genmab A/S	Outperform Votes 157 62.30%	Underperform Votes 95 37.70%

Is TAK or GMAB more profitable?

Genmab A/S has a net margin of 29.06% compared to Takeda Pharmaceutical's net margin of 6.02%. Genmab A/S's return on equity of 17.48% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	6.02%	10.11%	4.83%
Genmab A/S	29.06%	17.48%	15.13%

Do insiders & institutionals have more ownership in TAK or GMAB?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.